Navigation Links
VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
Date:2/6/2008

Comprehensive Cholesterol Test Can Help Identify Patients At Risk of Heart

Disease and Diabetes

BIRMINGHAM, Ala., Feb. 6 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced that the largest private insurers in Arizona as well as Medicare, Medicaid and the Federal Employees Health Benefits (FEHB) Program now cover the VAP (Vertical Auto Profile) Test, the most comprehensive cholesterol test available. That means almost 90 percent of all insured lives in Arizona now have insurance coverage for the VAP Test, which finds twice as many people at risk than the standard cholesterol test.

"The state of Arizona is extremely progressive in preventive health," said Atherotech Chief Medical Officer James Ehrlich, M.D. "The highly accurate VAP Test allows the clinician to target high-risk patients for specific therapy that could help prevent millions of future heart attacks and strokes. I am confident that the VAP Test will continue to be regarded as the best and most cost-effective laboratory method to precisely identify vulnerable individuals who may be at risk for the nation's leading killer, cardiovascular disease."

People with a family history or an existing condition of diabetes, high blood pressure or heart disease -- or who are already taking cholesterol lowering medication -- are candidates for the comprehensive VAP Test. In addition, those who didn't score within the desirable ranges of the standard cholesterol test (i.e. those with Triglycerides > 150, HDL < 40, LDL >130, Total Cholesterol > 200) should also opt for the more detailed VAP Test.

"The VAP cholesterol test allows a detailed analysis of all lipid parameters to obtain an accurate and predictive risk for CVD," said Richard Fowler, M.D., of the Arizona Center for Internal Medicine.

The VAP Test is the first cholesterol test to identify markers for Metabolic Syndrome, a precursor for diabetes. The VAP Test directly and accurately measures fifteen separate components of blood cholesterol compared to just three in a standard cholesterol test. This more comprehensive test has been shown to identify over twice the number of patients with lipid abnormalities than the standard lipid panel (cholesterol and triglyceride test). Risks of both heart disease and diabetes can be reduced with the right preventive treatments, which is why more accurate diagnosis is critical.

The VAP Test is available nationwide. Consumers interested in the test can ask their doctor for more information or visit http://www.thevaptest.com. Individuals should always check their plan for specific benefit coverage.

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on direct measurement of the comprehensive lipid panel using the company's VAP Technology. Specifically, the VAP technology is a patented density gradient ultracentrifugation that directly measures the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations calling for more accurate, direct, low-density lipoprotein (LDL) measurement, which is unaffected by triglycerides. Included in Forbes.com's list of "15 ways to Live Longer" and named one of "Five Tests Worth Paying For" by the Wall Street Journal, The VAP Cholesterol Test -- the new standard of care for patients at risk for cardiovascular disease -- is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit http://www.thevaptest.com.


'/>"/>
SOURCE Atherotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. New Survey Reveals Many Adults With High Cholesterol Fail to Take Necessary Steps to Improve Their Condition
2. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
3. Phase 1 Studies Show Promise of QuatRxs Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
4. Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination
5. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
6. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
7. 454 sequencing uncovers significant genetic variation
8. Medical Breakthrough ... Doctor Discovers Penetrating Carrier That Eradicates Fungus
9. deCODE Discovers Gene Variants that May Help to Distribute the Work of Evolution between Men and Women
10. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
11. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company ... Opinion Leader event to highlight new clinical data that ... at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the ... held in-person and via live webcast on Tuesday, February ... at the Lotte New York Palace Hotel in ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
(Date:2/23/2017)... , ... February 23, 2017 ... ... announced today that in a published evaluation of multiple immunoassay-based threat detection ... Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found ...
(Date:2/23/2017)... Aviva Systems Biology Corporation (ASB) which ... GenWay Biotech Incorporated, a protein solutions and applications ... for both the research and diagnostic markets. ... capabilities for both entities. GenWay,s 18 years of experience ... complement ASB,s objective to become a leading provider ...
Breaking Biology Technology:
(Date:1/26/2017)... , Jan. 26, 2017  Crossmatch, a leading ... a new solution aimed at combatting fraud, waste and ... was introduced at the Action on Disaster Relief conference ... meeting point for UN agencies and foreign assistance organizations ... Fraud, waste and abuse are a largely unacknowledged problem ...
(Date:1/24/2017)... YORK , Jan. 24, 2017 ... study of the laboratory use of nuclear magnetic ... 363 experienced end-users and profiled current practices, developments, ... years, as well as growth and opportunities. These ... Instrument suppliers, NMR instruments, needs and innovation requirements, ...
(Date:1/21/2017)... Jan 20, 2017 Research and Markets has ... 2017-2021" report to their offering. ... The global voice recognition biometrics market to ... The report covers the present scenario and the growth ... calculate the market size, the report considers the revenue generated from ...
Breaking Biology News(10 mins):